{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:48:23Z","timestamp":1776185303944,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-020-00370-8","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T11:20:56Z","timestamp":1607685656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":130,"title":["Characteristics and challenges of the clinical pipeline of digital therapeutics"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1697-6481","authenticated-orcid":false,"given":"Nisarg A.","family":"Patel","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-2740","authenticated-orcid":false,"given":"Atul J.","family":"Butte","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"370_CR1","unstructured":"Digital Therapeutics Alliance. https:\/\/dtxalliance.org (2020)."},{"key":"370_CR2","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1038\/d41586-019-02873-1","volume":"573","author":"S Makin","year":"2019","unstructured":"Makin, S. The emerging world of digital therapeutics. Nature 573, S106 (2019).","journal-title":"Nature"},{"key":"370_CR3","unstructured":"U.S. Food and Drug Administration. Enforcement policy for non-invasive remote monitoring devices used to support patient monitoring during the coronavirus disease 2019 (COVID-19) public health emergency (Revised). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-non-invasive-remote-monitoring-devices-used-support-patient-monitoring-during (2020)."},{"key":"370_CR4","unstructured":"U.S. Food and Drug Administration. Enforcement policy for digital health devices for treating psychiatric disorders during the coronavirus disease 2019 (COVID-19) public health emergency. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-digital-health-devices-treating-psychiatric-disorders-during-coronavirus-disease (2020)."},{"key":"370_CR5","unstructured":"Rachal, M. Digital therapeutic makers see opportunity as pandemic prompts FDA to ease rules. MedTechDive. https:\/\/www.medtechdive.com\/news\/digital-therapeutics-eye-opportunity-as-pandemic-prompts-fda-to-ease-rules\/576628\/ (2020)."},{"key":"370_CR6","unstructured":"European Medicines Agency. Regulatory science to 2025. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf (2020)."},{"key":"370_CR7","unstructured":"Pitchbook. https:\/\/pitchbook.com (2020)."},{"key":"370_CR8","unstructured":"reSET for Recovery. https:\/\/www.resetforrecovery.com\/how-it-works (2020)."},{"key":"370_CR9","unstructured":"reSET for Recovery. https:\/\/2kw3qa2w17x12whtqxlb6sjc-wpengine.netdna-ssl.com\/wp-content\/uploads\/2019\/08\/PEAR-MKT-024-reSET-Clin-Brief-Sum_Dec2019.pdf (2020)."},{"key":"370_CR10","unstructured":"Cognoa. Cognoa receives FDA breakthrough designation for autism diagnostic and digital therapeutic devices. https:\/\/cognoa.com\/cognoa-receives-fda-breakthrough-designations-for-autism-diagnostic-and-digital-therapeutic-devices\/ (2019)."},{"key":"370_CR11","unstructured":"U.S. Food and Drug Administration. Software Precetification Program: regulatory framework for conducting the Pilot Program within current authorities. https:\/\/www.fda.gov\/media\/119724\/download (2019)."},{"key":"370_CR12","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1126\/science.aay9547","volume":"366","author":"B Boris","year":"2019","unstructured":"Boris, B., Gerke, S., Evgeniou, T. & Cohen, G. I. Algorithms on regulatory lockdown in medicine. Science 366, 1202\u20131204 (2019).","journal-title":"Science"},{"key":"370_CR13","unstructured":"U.S. Food and Drug Administration. A history of medical device regulation & oversight in the United States. https:\/\/www.fda.gov\/medical-devices\/overview-device-regulation\/history-medical-device-regulation-oversight-united-states (2019)."},{"key":"370_CR14","unstructured":"U.S. Food and Drug Administration. Digital Health Software Precertification (Pre-Cert) Program. https:\/\/www.fda.gov\/MedicalDevices\/DigitalHealth\/DigitalHealthPreCertProgram\/default.htm (2019)."},{"key":"370_CR15","unstructured":"U.S. Food and Drug Administration. Proposed regulatory framework for modifications to artificial intelligence\/machine learning (AI\/ML)-based software as a medical device (SaMD)\u2014discussion paper and request for feedback. https:\/\/www.fda.gov\/media\/122535\/download (2019)."},{"key":"370_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-019-0211-0","volume":"3","author":"A Coravos","year":"2020","unstructured":"Coravos, A. et al. Modernizing and designing evaluation frameworks for connected sensor technologies in medicine. npj Digital Med. 3, 1\u201310 (2020).","journal-title":"npj Digital Med."},{"key":"370_CR17","unstructured":"U.S. Food and Drug Administration. Content of premarket submissions for management of cybersecurity in medical devices. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/content-premarket-submissions-management-cybersecurity-medical-devices (2018)."},{"key":"370_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025374","volume":"9","author":"AD Stern","year":"2019","unstructured":"Stern, A. D. et al. Cybersecurity features of digital medical devices: an analysis of FDA product summaries. BMJ Open 9, e025374 (2019).","journal-title":"BMJ Open"},{"key":"370_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/1468-0009.12278","volume":"95","author":"JG Ronquillo","year":"2017","unstructured":"Ronquillo, J. G. & Zuckerman, D. M. Software-related recalls of health information technology and other medical devices: implications for FDA regulation of digital health. Milbank Q 95, 535\u2013553 (2017).","journal-title":"Milbank Q"},{"key":"370_CR20","unstructured":"U.S. Food and Drug Administration. Postmarket management of cybersecurity in medical devices: guidance for industry and food and drug administration staff. https:\/\/www.fda.gov\/media\/95862\/download (2016)."},{"key":"370_CR21","unstructured":"Muoio D. CVS Health program for PBM clients adds five new digital health programs. Mobihealthnews. https:\/\/www.mobihealthnews.com\/news\/cvs-health-program-pbm-clients-adds-five-new-digital-health-programs (2020)."},{"key":"370_CR22","unstructured":"Welldoc. https:\/\/www.welldoc.com\/wp-content\/uploads\/2019\/11\/HCP-Reference-Manual-On-line_.pdf (2019)."},{"key":"370_CR23","unstructured":"U.S. Food and Drug Administration. Enforcement policy on national health related item code and national drug code numbers assigned to devices. https:\/\/www.fda.gov\/media\/95794\/download (2016)."},{"key":"370_CR24","unstructured":"Click Therapeutics. https:\/\/www.clicktherapeutics.com\/products\/ (2020)."},{"key":"370_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1176\/appi.ajp.2014.13081055","volume":"171","author":"AN Campbell","year":"2014","unstructured":"Campbell, A. N. et al. Internet-delivered treatment for substance abuse: a multi-site randomized controlled clinical trial. Am. J. Psychiat 171, 683\u2013690 (2014).","journal-title":"Am. J. Psychiat"},{"key":"370_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/0032885516636858","volume":"96","author":"M Chaple","year":"2016","unstructured":"Chaple, M. et al. A comparative study of the therapeutic education system for incarcerated substance-abusing offenders. Prison J. 96, 485\u2013508 (2016).","journal-title":"Prison J."},{"key":"370_CR27","unstructured":"Sandoz. Sandoz and Pear Therapeutics announce Pear will solely commercialize reSET and reSET-O. https:\/\/www.us.sandoz.com\/news\/media-releases\/sandoz-and-pear-therapeutics-announce-pear-will-solely-commercialize-reset-and (2019)."},{"key":"370_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1037\/a0037496","volume":"82","author":"DR Christensen","year":"2014","unstructured":"Christensen, D. R. et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J. Consult. Clin. Psych. 82, 964\u2013972 (2014).","journal-title":"J. Consult. Clin. Psych."},{"key":"370_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2215-0366(15)00536-2","volume":"3","author":"H Christensen","year":"2016","unstructured":"Christensen, H. et al. Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial. Lancet Psychiatry 3, 333\u2013341 (2016).","journal-title":"Lancet Psychiatry"},{"key":"370_CR30","unstructured":"Novartis. Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis. https:\/\/www.novartis.com\/news\/media-releases\/novartis-and-pear-therapeutics-develop-digital-therapeutics-patients-schizophrenia-and-multiple-sclerosis (2018)."},{"key":"370_CR31","unstructured":"Pear Therapeutics. Pear Therapeutics announces agreement with Ironwood Pharmaceuticals to evaluate prescription digital therapeutics for patients with GI indications. https:\/\/peartherapeutics.com\/pear-therapeutics-announces-agreement-with-ironwood-pharmaceuticals-to-evaluate-prescription-digital-therapeutics-for-patients-with-gi-indications\/ (2019)."},{"key":"370_CR32","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.2337\/dc11-0366","volume":"34","author":"CC Quinn","year":"2011","unstructured":"Quinn, C. C. et al. Cluster-Randomized Trial of a mobile phone personalized behavioral intervention for blood glucose control. Diabetes Care 34, 1934\u20131942 (2011).","journal-title":"Diabetes Care"},{"key":"370_CR33","unstructured":"Astellas. Astellas and Welldoc Enter into strategic alliance for digital therapeutics\u2014develop and commercialize digital health solutions globally for multiple therapeutic areas, including in Japan for diabetes patients. https:\/\/www.astellas.com\/en\/news\/15441 (2019)."},{"key":"370_CR34","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2589-7500(20)30017-0","volume":"2","author":"SH Kollins","year":"2020","unstructured":"Kollins, S. H. et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digital Health 2, e168\u201378 (2020).","journal-title":"Lancet Digital Health"},{"key":"370_CR35","unstructured":"Akili Interactive. Akili and Shionogi announce strategic partnership to develop and commercialize digital therapeutics in key Asian markets. https:\/\/www.akiliinteractive.com\/news-collection\/akili-and-shionogi-announce-strategic-partnership-to-develop-and-commercialize-digital-therapeutics-in-key-asian-markets (2019)."},{"key":"370_CR36","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s10803-018-3856-7","volume":"49","author":"BE Yerys","year":"2019","unstructured":"Yerys, B. E. et al. Brief report: pilot study of a novel interactive digital treatment to improve cognitive control in children with autism spectrum disorder and co-occurring ADHD symptoms. J. Autism Dev. Disord. 49, 1727\u20131737 (2019).","journal-title":"J. Autism Dev. Disord."},{"key":"370_CR37","unstructured":"Otsuka. Otsuka and Click Therapeutics collaborate to develop and commercialize digital therapeutics for patients with major depressive disorder. https:\/\/www.otsuka-us.com\/discover\/otsuka-and-click-therapeutics-collaborate (2019)."},{"key":"370_CR38","unstructured":"U.S. National Library of Medicine. Cognoa Autism Spectrum Disorder (ASD) Digital Therapeutic Engagement and Usability Study. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04326231 (2020)."},{"key":"370_CR39","unstructured":"Hale C. Novartis taps growing Biofourmis for digital Heart Failure project. Fierce Biotech. https:\/\/www.fiercebiotech.com\/medtech\/novartis-taps-growing-biofourmis-for-digital-heart-failure-project (2020)."},{"key":"370_CR40","unstructured":"U.S. National Library of Medicine. Kardia\u2014a smartphone-based care model for outpatient cardiac rehabilitation. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03415841 (2020)."},{"key":"370_CR41","unstructured":"U.S. National Library of Medicine. Objective pain measurement using a wearable biosensor and a mobile platform in patients with endometriosis (OPINE). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318275 (2020)."},{"key":"370_CR42","unstructured":"H. C. Biofourmis, Chugai to develop wearable for digitally measuring endometriosis pain. Fierce Biotech. https:\/\/www.fiercebiotech.com\/medtech\/biofourmis-chugai-to-develop-wearable-for-digitally-measuring-endometriosis-pain (2020)."},{"key":"370_CR43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaip.2015.11.022","volume":"4","author":"RK Merchant","year":"2016","unstructured":"Merchant, R. K., Inamdar, R. & Quade, R. C. Effectiveness of population health management using the propeller health asthma platform: a randomized clinical trial. J. Allergy Clin. Immunol.-Pract. 4, 455\u2013463 (2016).","journal-title":"J. Allergy Clin. Immunol.-Pract."},{"key":"370_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/jamp.2017.1383","volume":"31","author":"K Sumino","year":"2018","unstructured":"Sumino, K. et al. Use of a remote inhaler monitoring device to measure change in inhaler use with chronic obstructive pulmonary disease exacerbations. J. Aerosol Med. Pulm. Drug Deliv. 31, 191\u2013198 (2018).","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"370_CR45","unstructured":"Hale, C. AstraZeneca spins up new partnership with Propeller Health to add smart features to its Symbicort inhaler. Fierce Biotech. https:\/\/www.fiercebiotech.com\/medtech\/astrazeneca-spins-up-new-partnership-propeller-health-to-add-smart-features-to-its"},{"key":"370_CR46","unstructured":"U.S. National Library of Medicine. Virtual reality trial using EaseVRx for chronic low back pain. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04415177 (2020)."},{"key":"370_CR47","unstructured":"U.S. National Library of Medicine. RelieVRx for total knee arthroplasty (TKA) for the reduction of acute postoperative pain and opioid use. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04010266 (2020)."},{"key":"370_CR48","unstructured":"Sanofi. Sanofi and Happify Health solidify collaboration around prescription DTx designed to address mental health in people with MS. https:\/\/www.sanofi.com\/en\/media-room\/articles\/2019\/happify-collaboration (2019)."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00370-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T01:30:00Z","timestamp":1670376600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00370-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1038\/s41746-020-00370-8","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"assertion":[{"value":"24 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.A.P. is a cofounder of and shareholder in Memora Health Inc. and receives personal fees as a consultant for Bessemer Venture Partners. A.J.B. is a cofounder of and consultant to Personalis and NuMedii; consultant to Samsung, Geisinger Health, Mango Tree Corp., Regenstrief Institute, and, in the recent past, 10x Genomics and Helix; shareholder in NuMedii and Personalis; and minor shareholder in Apple, Facebook, Google, Microsoft, 10x Genomics, Amazon, Biogen, Regeneron, Moderna, Illumina, Snap, Sutro, Sanofi, and several other non-health-related companies and mutual funds. He has received honoraria and travel reimbursement for invited talks from Genentech, Roche, Pfizer, Merck, Lilly, Mars, Siemens, Optum, AbbVie, Westat, and many academic institutions, medical or disease-specific foundations and associations, and health systems. AJB receives royalty payments through Stanford University for several patents (US20160018413, WO2013169751, US2013039918, US20130080068, US20130116931, US20130090909, US20120101736, WO2011094731, and US20130071408) and other disclosures licensed to NuMedii and Personalis and Carmenta (now Progenity). AJB\u2019s research has been funded by Northrop Grumman (as the prime on an NIH contract), Genentech, and, in the recent past, L\u2019Or\u00e9al and Progenity.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}